Meet us this year at BIO, the largest global non-profit biotechnology trade association. On Tuesday, June 14th, our CEO Colin Hill, will be moderating a panel discussion titled “Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs”. He will be joined by Andrea de Souza, AVP Global Head, Data Sciences and Engineering, Eli Lilly and Company; Steffan Ho, MD, PhD, VP and Head of Translational Oncology, Pfizer Global Product Development; John Quackenbush, Chair, Department of Biostatistics and Professor, Computational Biology, Harvard T.H. Chan School of Public Health and Sid Roychoudhury, PhD, Program Strategy Leader, Gilead Sciences.

This panel will showcase recent examples in digital, AI, and in-silico models that highlight this new reality and the real potential to decrease the timelines around clinical trials, speed up drug development, and ultimately improve patient care.

Panel session | 1:45 PM – 2:45 PM PDT | Upper Level, Session Room 3

More information: